arrow
M

Matthew J. Walter

Washington University in St Louis
H指数:55
被引数:2.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

TET2 loss triggers ssDNA gap accumulation and heightened PARP inhibitor sensitivity

TET2缺失引发单链DNA缺口积累和增强的PARP抑制剂敏感性

2026-09-120
OA
A Phase Ib/II study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML

Ib/II期研究:ceralasertib(一种ATR选择性抑制剂)在复发或难治性MDS和CMML患者中的研究

2026-07-020
OA
Clinical, Genetic, and Pathologic Variability in Myelodysplastic Syndromes and Precursor Conditions Across Race, Ethnicity, and Sex

骨髓增生异常综合征及前体状态在种族、族裔和性别方面的临床、遗传和病理学变异

2026-03-290
OAAI
Exposure to Agent Orange and Association with Myelodysplastic Syndromes

暴露于橙剂及其与骨髓增生异常综合征的关联

2026-03-020
OA
Modeling the evolutionary dynamics of clonal hematopoiesis

模拟克隆性造血的进化动力学

2026-02-160
PRE
Evaluation of long-read genome sequencing for genomic profiling of myeloid cancers

长读长基因组测序在髓系肿瘤基因组分析中的应用评估

2025-09-260
PRE
Germline genetic variation impacts clonal hematopoiesis landscape and progression to malignancy

种系遗传变异影响克隆造血景观和发展为恶性肿瘤

2025-07-150
OAAI
Progression of Myelodysplastic Syndromes in the MDS Natural History Study (MDS NHS)

骨髓增生异常综合征在MDS自然史研究(MDS NHS)中的进展

BLOOD
IF23.1
2024-11-050
PRE
Clearance of Leukemia Associated Mutations (LAMs) after Induction Therapy Is Associated with Favorable Outcomes in Intermediate Risk Acute Myeloid Leukemia: Interim Results of a Multicenter, Prospective Phase II Trial

白血病相关突变(LAMs)在诱导治疗后清除与中危急性髓系白血病的不良预后相关:一项多中心、前瞻性II期试验的 interim 结果

BLOOD
IF23.1
2024-11-050
PRE
Monitoring clonal burden as an alternative to blast count for myelodysplastic neoplasm treatment response
LEUKEMIA
IF13.4
2024-10-040
PRE
Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk

血浆蛋白质组学特征预测髓系肿瘤风险

2024-03-063
OAAI
R-Loop Accumulation in Spliceosome Mutant Leukemias Confers Sensitivity to PARP1 Inhibition by Triggering Transcription-Replication Conflicts
2023-11-156
OA